Extracranial Oligometastasis in Non-Small Cell Lung Cancer

Arturo Navarro-Martin, Consuelo Jordán de Luna, Rafael Fuentes, M Dolores Arnàiz Fernández and Josep Jové

Radiation Oncology Department, Catalan Institute of Oncology, Spain
Duran i Reynals Hospital, Catalan Institute of Oncology, Spain
Radiation Oncology Department, Catalan Institute of Oncology, Spain
Radiation Oncology Department, Catalan Institute of Oncology, Spain

^*Correspondance to: Arturo Navarro-Martin 

 PDF  Full Text Research Article | Open Access

Abstract:

Classically, the main treatment approach to metastatic non-small cell lung cancer (NSCLC) has been chemotherapy, achieving a mean survival time of only 8 to 11 months. However, a subset of these patients has a better prognosis and could benefit from radical local treatment. At present, the evidence to support SBRT in oligometastatic NSCLC is limited, despite the increasing number of clinical trials being carried out to evaluate SBRT as monotherapy or in combination with immunomodulatory therapies. Based on the available data, it appears that only 10-15% of patients with oligometastatic disease are likely to benefit from local radical treatment. This subset of patients who are likely to respond well to SBRT should meet certain criteria.

Keywords:

Cite the Article:

Navarro-Martin A, de Luna CJ, Fuentes R, Fernández MDA, Jové J. Extracranial Oligometastasis in Non- Small Cell Lung Cancer. Clin Oncol. 2018; 3: 1397.